Pipeline

Summary: Axsome Therapeutics’ Q1 2024 report highlights advancements in its sleep medicine pipeline, with positive phase 3 results for AXS-12 in narcolepsy treatment and revenue growth for Sunosi, reflecting strong financial performance and progress in addressing sleep disorders. Additionally, the company showcases promising developments in its neuroscience portfolio, including ongoing clinical trials for solriamfetol in […]